Novalis Biotech is an early stage venture capital fund in life sciences. The firm’s investment ideas focus on the interaction between bio-informatics and life sciences. The firm strongly believes in applying innovative information technology to advance prevention, diagnosis, or treatment of diseases. Novalis focuses on capital light business models and platform technology. As an early stage private equity/venture capital fund, they are a dynamic and flexible player not restricting themselves to specific fields of expertise, but open to discuss any proposition in the field of life-sciences. The firm differentiates themselves by high dynamism and flexibility to rapidly evolve their portfolio companies.
Novalis Biotech is interested in the diagnostics and digital health sectors. Within diagnostics, the firm is opportunistic and will consider technologies, services, and tools in development phases. Within digital health, the firm is opportunistic with interests including bioinformatics. The firm does not invest in clinical trials and will not consider traditional pharmaceuticals or medtech sectors. Indications of interest include oncology and neurology.
Novalis Biotech highly values working with a top management team that is committed to the project. The firm acts as a lead investor and will require board seating.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment